HC Wainwright & Co. Maintains Buy Rating for BioLine Rx: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
HC Wainwright & Co. has maintained its Buy rating for BioLine Rx (NASDAQ:BLRX) and raised its price target from $19.00 to $21.00. BioLine Rx's shares are trading up 11.36% over the last 24 hours. The new price target would account for a 971.43% increase from the current share price. BioLine Rx is a pre-commercial-stage biopharmaceutical company focused on oncology.
September 15, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has maintained its Buy rating for BioLine Rx and raised its price target, indicating a positive outlook for the company. The stock is currently trading up 11.36%.
The decision by HC Wainwright & Co. to maintain a Buy rating and raise the price target for BioLine Rx indicates a positive outlook for the company's stock. This is likely to attract investors, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100